Lantheus Appoints Dr. P.K. Morrow, Oncology Executive, to Board of Directors
Lantheus Holdings appointed Phuong Khanh (P.K.) Morrow, M.D., a former pharmaceutical executive focused on oncology, to its board of directors, effective February 1, 2025. The board expanded to eleven directors, nine of whom are independent, and Dr. Morrow will sit on the Science and Technology Committee. The filing describes a board seat, not a change in financial results or guidance.
Key points
- Dr. Morrow was appointed by the board on January 29, 2025 and is effective February 1, 2025.
- Board size increased to eleven directors; Dr. Morrow is a Class II Director with a term expiring at the 2026 annual meeting.
- Director compensation: $60,000 annual cash retainer, $7,500 for Science and Technology Committee service, a $100,000 initial grant, and a $400,000 annual equity grant starting in 2025.
- Dr. Morrow was previously Chief Medical Officer at CRISPR Therapeutics and held roles at Amgen; she currently leads oncology R&D at Takeda.
The filing
Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 30, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.